在全球擁有近18000個訂戶，癌癥研究是基礎(chǔ)和臨床腫瘤學(xué)領(lǐng)域最受重視和認可的期刊之一。它旨在為醫(yī)生提供癌癥領(lǐng)域當(dāng)前進展?fàn)顩r的全面資源，以及有效決策所需的可靠信息的廣泛背景。除了發(fā)表具有重要意義的原始論文外，它還發(fā)表評論、論文、爭議的專門介紹、對新技術(shù)及其在具體實驗室問題上的應(yīng)用的考慮、公共問題的討論、關(guān)于主要主題的小系列、新的和實驗性藥物和療法，以及致編輯部的無創(chuàng)意信函。《華爾街日報》的一個獨特之處是其部門化的編輯部分，報告了30多個學(xué)科類別，涵蓋了廣泛的專門領(lǐng)域，這些領(lǐng)域共同構(gòu)成了腫瘤學(xué)領(lǐng)域。由主要的醫(yī)生和研究科學(xué)家編輯，這些部分使癌癥調(diào)查成為臨床醫(yī)生尋求理解這個領(lǐng)域中有時大量信息的主要資源。除了同行評審的臨床研究外，該雜志還以翻譯研究為特色，彌合實驗室和臨床之間的差距。

With nearly 18,000 subscribers worldwide, Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.